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AbstrACt
Introduction Enzalutamide and abiraterone acetate 
plus prednisolone (AAP) are used in combination with 
androgen-deprivation therapy to further suppress the 
androgen stimulation of metastatic castration-resistant 
prostate cancer (mCRPC). First-line mCRPC treatment 
with enzalutamide and AAP yields similar overall survival 
and radiographic progression-free survival in phase III 
trials. Thus, treatment selection relies on patient choice, 
cost and side effects. The aim of this randomised trial 
is to investigate differences in fatigue, health-related 
quality of life (HRQoL) and metabolic side effects in men 
with mCRPC treated with first-line enzalutamide versus 
AAP.
Methods and analysis In this ongoing open-label 
randomised (1:1) clinical trial, enzalutamide is compared 
with AAP as first-line treatment for men with mCRPC. 
The primary endpoint is fatigue assessed with the 
questionnaire Functional Assessment of Chronic Illness 
Therapy-Fatigue version 4. Secondary endpoints are 
changes in body composition (ie, fat mass, visceral 
adipose tissue, subcutaneous adipose tissue and lean body 
mass assessed with dual energy X-ray absorptiometry), 
glucose metabolism assessed with a 2-hour oral glucose 
tolerance test, serum lipids, blood pressure and HRQoL 
assessed with the questionnaire Functional Assessment of 
Cancer Therapy-Prostate (FACT-P). All study endpoints are 
assessed at baseline and 12-week postintervention. Blood 
and urine samples are collected at baseline and at time of 
progression on allocated treatment for future investigation 
of predictive and prognostic biomarkers in prostate cancer 
treatment. The planned sample size is 170 participants. 
All participants are recruited from Herlev and Gentofte 
Hospital, Denmark. Estimated last patient’s last visit is 
February 2020.
Ethics and dissemination The study received project 
approval from the National Committee on Health Research 
Ethics and Danish Data Protection Agency and Danish 
Medicines Agency (EudraCT no.: 2017-000027-99). The 
results of the study will be published in peer-reviewed 
international journals and will be presented at national and 
international conferences and symposiums.
trial registration number  Clin ical tria lsre gister. eu (2017-
000099-27).
IntroduCtIon
During the past decade, several new treat-
ment options have emerged for metastatic 
castration-resistant prostate cancer (mCRPC). 
These new treatment options include the 
androgen pathway inhibitors enzalutamide 
and abiraterone acetate. Enzalutamide blocks 
several steps in the androgen receptor signal-
ling. Abiraterone inhibits enzymes (17a-hy-
droxylase and 17,20-lyase) in the androgen 
biosynthesis, and is combined with predniso-
lone to compensate for abiraterone-induced 
reductions in serum cortisol.1 2
Enzalutamide and abiraterone acetate 
plus prednisolone (AAP) yield similar radio-
graphic progression-free and overall survival 
results in the phase III trials (PREVAIL and 
COU-AA-302, respectively) which has led to 
strengths and limitations of this study
 ► This randomised clinical trial will report patient-re-
ported and metabolic side effects in a relatively 
large sample size.
 ► This is the first randomised head-to-head trial pri-
marily comparing fatigue, health-related quality of 
life and metabolic side effects in men with meta-
static castration-resistant prostate cancer treated 
with first-line enzalutamide versus abiraterone plus 
prednisolone.
 ► The trial lacks assessment of long-term side effects.
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approval as first-line mCRPC treatments.3–6 Thus, the 
choice between these two agents depends on the patient’s 
preference, costs and agent-specific side effects.
Men with mCRPC that have been treated with andro-
gen-deprivation therapy (ADT), have an increased risk of 
metabolic side effects and fatigue affecting health-related 
quality of life (HRQoL).7 8 Androgen pathway inhibitors 
are generally safe, with low rates of grade 3 and 4 adverse 
events. Most of the reported adverse events of these treat-
ments are similar in the mentioned phase III trails, but 
the following adverse events were different: enzalutamide 
was associated with memory impairment and seizures; 
whereas AAP was associated with liver function abnormal-
ities, peripheral oedema and cardiac events.3 5 9 Fatigue 
was the most common reported adverse event of both 
enzalutamide and AAP, although commonly emphasised 
as a side effect to enzalutamide.3 5 Comparing the results 
of the two trials is difficult, as the men in the control group 
of the enzalutamide trial (PREVAIL) received placebo, 
whereas the men in the control group of the AAP trial 
(COU-AA-302) received placebo plus prednisone.3 5 To 
date, no randomised head-to-head comparison primarily 
exploring differences in the side effect profiles have, to 
our knowledge, been published.
In addition, AAP has been approved for hormone-
naïve metastatic prostate cancer and enzalutamide is 
expected to gain similar approval10–12 (NCT02677896, 
NCT02319837). This change in treatment sequencing 
will result in longer exposure to side effects, making 
comparative studies with specific side effect endpoints 
even more essential.
This protocol describes an ongoing randomised clin-
ical trial comparing self-reported fatigue and HRQoL and 
metabolic changes in men treated with enzalutamide or 
AAP as first-line treatment for mCRPC. The aim is that 
the results from this trial may help patients and physi-
cians to choose the best tolerated treatment based on the 
difference in the side effects of enzalutamide and AAP.
MEthods And AnAlysIs
trial design
This is a single-centre open-labelled randomised (1:1) 
phase IV trial comparing first-line enzalutamide versus 
AAP in men with mCRPC. The trial is conducted at the 
Department of Urology, Herlev and Gentofte Hospital, 
Denmark. The primary objective is to compare fatigue 
assessed with the questionnaire Functional Assessment of 
Chronic Illness Therapy-Fatigue (FACIT-Fatigue) version 
4.
Participants
Eligible participants are men with newly diagnosed 
mCRPC, defined as metastatic prostate cancer progressing 
on ADT, based on the prostate cancer working group 3 
criteria.13 Metastatic status is measured with computed 
tomography (CT) scan of the thorax and abdomen 
and bone imaging (18F-sodium fluoride positron 
emission tomography-CT (PET/CT) or prostate-spe-
cific membrane antigen PET/CT). Inclusion criteria are 
age ≤90 years, an Eastern Cooperative Oncology Group 
performance status 0–1 and adequate organ function 
(creatinine <1.5 x the upper limit of normal (ULN), 
total bilirubin <1.5 x ULN and alanine aminotransferase 
or aspartate aminotransferase ≤2.5 x ULN). Exclusion 
criteria are visceral metastases, a prior history of seizures, 
known heart failure (New York Heart Association func-
tional class >2), diabetes mellitus, hypersensitivity to or 
previous treatment with enzalutamide or AAP or previous 
treatment with docetaxel. An exception to the latter 
is docetaxel in the metastatic hormone-naïve prostate 
cancer setting, if the treatment was completed >6 months 
prior to enrolment. Inclusion and exclusion criteria are 
depicted in table 1. Eligibility is primarily assessed at 
the department’s multidisciplinary team conference, 
where all patients are evaluated prior to starting first-line 
mCRPC treatment. Subsequently, eligibility is confirmed 
by the primary investigator at a screening consultation 
before randomisation. This ensures that all eligible men 
at Herlev and Gentofte Hospital are offered study partic-
ipation. The timeline from screening to intervention is 
depicted in figure 1.
randomisation
Patients who meet the inclusion and exclusion criteria and 
have given a written informed consent are randomised 
at the screening consultation using the Randomization 
Module of Research electronical data capture (REDCap 
V.7.1.1). The allocation sequence is a computer-gener-
ated list of random numbers transferred to REDCap by 
a collaborator with no clinical involvement in the trial. 
Participants are randomly assigned to either enzalut-
amide or AAP in a 1:1 ratio without stratification. Rando-
misation follows a block randomisation with 60 men in the 
first block and 110 men in the last block. Participants and 
physicians are aware of the allocation arm after randomis-
ation. Data and outcome assessors are not blinded.
Interventions
Recruitment began in June 2017 and planned completion 
is December 2019. Herlev and Gentofte Hospital provides 
urological cancer care for a population of ~1.3 million. 
We estimate that around 150 men are offered either 
enzalutamide or AAP as first-line mCRPC treatment 
yearly at the Department of Urology, Herlev and Gentofte 
Hospital. Participants are randomised to receive one of 
the following treatments.
Enzalutamide
Participants are allocated to take 160 mg enzalutamide 
orally in the evening.
Abiraterone acetate plus prednisolone
Participants are allocated to take 1000 mg abiraterone 
acetate orally at least 1 hour before a meal or 2 hours after 
a meal in the evening.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Eligible for first line treatment with either enzalutamide or 
abiraterone acetate plus prednisolone as per standard of care 
guidelines.
 ► Age 18–90 years.
 ► Willing, capable and legally competent individuals.
 ► ECOG performance status 0–1.
 ► Histologically confirmed adenocarcinoma of the prostate.
 ► Prior surgical orchiectomy or if on LHRH agonist/antagonist, 
then testosterone <1.7 nmol/L at screening visit (participants 
must maintain LHRH agonist/antagonist therapy for duration of 
study treatment if not surgically castrated).
 ► Evidence of metastatic disease on bone imaging or CT scan.
 ► Evidence of biochemical or imaging progression in the setting 
of surgical or medical castration. Progressive disease for 
study entry is defined by one of the following criteria based on 
criteria of PCWG3:
 – Biochemical progression: obtain sequence of rising PSA 
values at a minimum of 1 week intervals, resulting in 
increases over the nadir, with PSA >1 ng/mL.
 – Radiological progression:
 – The appearance of two or more new bone lesions on 
bone imaging.
 – Enlargement of a soft tissue lesion using the modified 
RECIST V.1.1.
 ► Adequate organ function defined as:
 – Creatinine <1.5 x ULN.
 – Total bilirubin <1.5 x ULN.
 – ALT or AST≤ 2.5 x ULN.
 ► Inability to understand and/or stick to the written information.
 ► Previous treatment with docetaxel, with the exception of 
previous treatment with early docetaxel (≤6 series) ≥6 months 
before inclusion.
 ► Diagnosed with diabetes mellitus and/or HbA1C>48 mmol/mol.
 ► Hypersensitivity towards components in abiraterone acetate 
plus prednisolone or enzalutamide.
 ► Ongoing treatment with high doses of glucocorticoids.
 ► Severe concurrent illness or comorbid disease that would make 
the subject unsuitable for enrolment.
 ► Prior therapy with CYP17 inhibitors, enzalutamide or other 
experimental antiandrogens.
 ► Life expectancy <6 months.
 ► Active concurrent malignancy.
 ► Treatment with Radium-223.
 ► Known brain metastases.
 ► Liver or lung metastases on CT scanning.
 ► History of seizure or seizure disorder, or history of 
cerebrovascular stroke within 6 months of study entry.
 ► Known cardiac failure (>NYHA class II).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CYP17, 17a-hydroxylase and 17, 20-lyase; ECOG, Eastern Cooperative 
Oncology Group; HbA1C, glycated haemoglobin; LHRH, luteinising hormone-releasing hormone; NYHA, New York Heart Association; 
PCWG3, Prostate Cancer Working Group 3; PSA, prostate-specific antigen; RECIST, Response Evaluation Criteria in Solid Tumours; 
ULN, upper limit of normal.
Figure 1 Timeline from screening to intervention.
Participants are instructed to take 10 mg prednisolone 
orally in the morning.
Compliance is ensured by registering the number of 
returned tablets at the follow-up visit. During the trial, all 
participants continue ADT. In addition, all participants 
follow normal standard of care and monitoring according 
to local and national guidelines at the Department of 
Urology, Herlev and Gentofte Hospital, such as being 
offered bone protecting agents (ie, denosumab and 
calcium and vitamin D supplements). Participants receive 
allocated treatment from baseline visit until biochem-
ical and/or radiographic progression or at the treating 
physician’s discretion after which appropriate choice of 
second-line mCRPC treatment will be decided at multidis-
ciplinary team conferences as per standard of care.
outcomes
Measurements
Primary and secondary outcomes are assessed for all 
participants at baseline and 12-week post-intervention by 
the primary investigator. A schedule of enrolment, inter-
ventions and assessments is depicted in table 2.
Primary outcome
The primary endpoint is the between-group differences in 
changed level of fatigue assessed with the 13-question ques-
tionnaire FACIT-Fatigue available and validated in Danish. 
The participants report the past week’s experienced 
fatigue by grading each question from one to four: ‘not at 
all’, ‘a little bit’, ‘some-what’, ‘quite a bite’ and ‘very much’. 
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Follow-up at time of
disease progression
Time (weeks from treatment 
initiation)
−2±2 0 +12 ± 2 +10 until the year 
2023
  Written informed consent X       
  Medical history X X     
  Medication list X X X   
  ECOG performance status X X X   
Physical         
  Height   X     
  Blood pressure, weight, BMI   X X   
Questionnaires         
  FACIT-Fatigue   X X X
  FACT-P   X X X
Samples         
  Blood samples   X X X
  Urine sample   X   X
Other paraclinical examinations         
  DXA scan   X X   
  OGTT (only the first 60 
participants)
  X X   
Safety         
  Adverse events     X   
BMI, body mass index; DXA, dual energy X-ray absorptiometry; ECOG, Eastern Cooperative Oncology Group; FACIT-Fatigue, Functional 
Assessment of Chronic Illness Therapy-Fatigue; FACT-P, Functional Assessment of Cancer Therapy-Prostate; OGTT, oral glucose tolerance 
test.
A minimal clinical important difference (MCID) in fatigue 
is defined as a 3.0 points change on an individual level.14 
Fatigue is assessed at baseline, 12-week postintervention 
and at time of disease progression on allocated treatment.
Secondary outcomes
The secondary outcomes are the between-group differ-
ences in changed HRQoL, body composition, blood pres-
sure, insulin sensitivity and resistance measured with a 
4-point oral glucose tolerance test (OGTT), serum lipids 
and androgen treatment response.
Health-related quality of life
The between-group change in HRQoL is assessed with 
the 39-question questionnaire Functional Assessment of 
Cancer Therapy—Prostate (FACT-P) version 4 available 
and validated in Danish. FACT-P is assessed with the same 
grading as the FACIT-Fatigue questionnaire. An MCID in 
HRQoL is defined as a six points change on an individual 
level.15 HRQoL is assessed at baseline, 12-week postinter-
vention and at time of disease progression on allocated 
treatment.
Body composition
Fat mass, body fat %, visceral adipose tissue volume (VAT), 
subcutaneous adipose tissue volume (SAT) and lean 
body mass (LBM) are obtained using DXA whole body 
fan-beam scans (Hologic Discovery, Bedford, Massachu-
setts, USA) with the software APEX V.4.0. VAT and SAT 
are measured in a 5 cm wide horizontal slice across the 
abdomen from the iliac crest to the L4-L5 segment.16 17 
Weight (BWB-800A, TANITA, Tokoyo, Japan) and body 
mass index (height in meters2/weight in kilograms) is 
assessed as well. Systolic and diastolic blood pressure is 
measured on the right arm after at least 20 min of rest (BP 
A3 Plus, Microlife AG, Widnau, Switerland).
Oral glucose tolerance test
The first 60 participants undergo a 2-hour OGTT (75 g 
glucose) after at least 9 hours of fasting. Plasma glucose 
and insulin are measured after 0, 30, 60 and 120 min. 
The whole body insulin sensitivity index (Matsuda 
index) are calculated from plasma glucose and insulin 
concentrations attained from the 2-hour OGTT in the 
subgroup of 60 participants.18 The equation for calcu-
lating the Matsuda index is: 10.000/√ (FPG×FPI × mean 
PG ×mean PI). FPG is the fasting plasma glucose and 
FPI is the fasting plasma insulin concentration. Fasting 
plasma glucose and insulin are measured in all 170 
participants. Fasting insulin resistance is calculated from 
the basal glucose and insulin concentrations using the 
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homeostatic model assessment with following equation: 
(FPG×FPI)/22.5.19
Biochemical assays
All blood samples are drawn before 11 am after a 
minimum of 9 hours of fasting.
Metabolic analyses
Plasma glucose is analysed with an enzymatic assay (Vitros 
5.1, Ortho-Clinical Diagnostics, USA). Plasma insulin is 
analysed with a enzyme immunoassay (DRG instruments 
GmbH, Germany). Glycated haemoglobin (HbA1c) is 
measured by high-performance liquid chromatography 
(Variant II TURBO, Bio-RAD, USA). Triglycerides, total 
cholesterol, high density lipoprotein cholesterol, low 
density lipoprotein cholesterol and very low density lipo-
protein cholesterol are assayed by an enzymatic tech-
nique (Vitros 5.1 FS, Ortho-Clinical Diagnostics, USA). 
C reactive protein is analysed with a latex-enhanced 
immuno-turbidimetric test (Atellica CH 930, Siemens, 
Germany).
Androgen treatment response
Serum total testosterone, androstenedione, dehydroe-
piandrosterone sulfate and 17-hydroxyprogesterone are 
measured by liquid chromatography—tandem mass spec-
trometry (Acquity UPLC Xevo TQ MS, Waters, USA). Sex 
hormone-binding globulin is analysed by a competitive 
chemiluminescence based immunoassay (Cobas, Roche 
Diagnostics, Mannheim, Germany). Plasma luteinising 
hormone and follicle-stimulating hormone are measured 
using sandwich chemiluminescence immunoassay 
(ADVIA Centaur, Siemens, Germany).
Additional measurements
Common terminology criteria for adverse events
Adverse events will be registered at the 12-week postinter-
vention visit, using the common terminology criteria for 
adverse events V.4.20
Metabolic biomarkers
Samples of full blood and serum are prospectively 
collected at baseline and 12-week postintervention for 
future assessment of cardiac, adipose and inflammatory 
biomarkers.
Genetic biomarkers
A biobank is generated during the trial and will be used 
for a future prospective, observational study assessing the 
predictive and prognostic value of genetic biomarkers 
in circulating cell-free DNA (ccfDNA). Samples from 
blood and urine are prospectively collected at baseline 
and at time of disease progression on allocated treat-
ment. Somatic alterations will be analysed from ccfDNA 
in plasma, urine pellets and supernatant.
Patient and public involvement
The patients treated with enzalutamide and AAP inspired 
us to the design of the trial’s research question and 
outcomes, by sharing their experience of the treatment 
and associated side effects in the out-patient clinic of 
Herlev and Gentofte Hospital. Fatigue is the primary 
outcome of the trial, since fatigue is the most common 
and distressing symptom experienced by patients with 
mCRPC.21 The burden of the intervention is partly 
assessed by patient-reported questionnaires assessing 
fatigue and HRQoL. Patients were not involved in the 
recruitment to or conduct of the trial. The results of the 
trial will be made publicly available through the home-
page of Herlev and Gentofte Hospital.
sample size and statistical analysis
The sample size calculation is based on the detection of 
a between-group MCID of 3.0 points on the FACIT-Fa-
tigue scale, with an anticipated drop-out of 10%.14 The 
standard deviation is assumed to be 6.55, based on confi-
dence limits from previous studies assessing fatigue in 
men with metastatic prostate cancer.22–24 The sample size 
calculation is based on a two‐tailed significance level of 
5% and a power of 80%. This required a sample size of 85 
participants in each group, a total of 170 men.
The within-subject and between-group differences of 
the primary and secondary endpoints will be analysed 
with linear mixed effect models using constrained longi-
tudinal analysis (cLDA). The between-group MCID in 
fatigue and HRQoL will be analysed with risk difference. 
An MCID in fatigue is defined as an individual 3-point 
change in the FACIT-Fatigue total score. An MCID in 
HRQoL is defined as an individual 6-point change in 
FACT-P total score. Interactions between patient-reported 
outcomes (fatigue and quality of life), and age (<75 vs 
≥75 years) and extent of metastases (high vs low volume 
disease) will be tested in sub-group analyses using forest 
plots. High volume disease is defined as ≥4 bone metas-
tases with ≥1 bone metastases outside pelvis and column. 
Interactions between metabolic changes, and body mass 
index (BMI) (<30 vs ≥30) and age (<75 vs ≥75 years) will 
be analysed in subgroup analyses using forest plots. The 
linear mixed effect model using cLDA handles random 
missing data.
EthICs And dIssEMInAtIon
Participants will receive standard first-line treatment for 
mCRPC. The primary investigator obtains the written 
informed consent from all participants. The trial follows 
the International Conference on Harmonization Good 
Clinical Practice guidelines, the latest revision of the 
Declaration of Helsinki and the Danish rules on Clinical 
Trials of Medicines in Humans. The trial is externally 
monitored by Good Clinical Practice Unit, Copenhagen 
University. The trial’s results will be published in peer-re-
viewed international journals or otherwise made publicly 
available and will be presented at national and inter-
national conferences and symposiums irrespective of 
the outcomes. Patient-reported outcome, metabolic 
changes, hormone analyses and genetic biomarkers will 
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be reported in separate publications. Study completion is 
expected by spring 2020, and dissemination of the results 
will begin as soon as possible thereafter.
dIsCussIon
This article describes the protocol of an ongoing 
randomised clinical trial comparing fatigue, HRQoL and 
metabolic changes in men with mCRPC treated with first-
line enzalutamide versus AAP.
We chose fatigue as the primary endpoint since it is 
the most common and distressing symptom affecting 
HRQoL in men with mCRPC.3 5 25 26 We assess changes 
in patient-reported fatigue with the validated 13-ques-
tion questionnaire FACIT-Fatigue. Previous randomised 
clinical trials on enzalutamide and AAP measured the 
level of fatigue with Common Terminology Criteria for 
Adverse Event with a coarse three-level grading, from 
fatigue ‘relieved by rest’ to fatigue ‘limiting self-care’.3 5 
We expect that changes in fatigue will be reported more 
accurately from patients using the 13-question question-
naires in contrast to the physician reported three-level 
grading used in previously trials. We did not choose to 
assess fatigue by interviews since that would preclude a 
statistical comparison of changes in fatigue, even though 
interviews might yield a more individual assessment of 
fatigue.
We chose to assess changes in patient-reported HRQoL 
with the 39-question questionnaire FACT-P, because 
FACT-P is developed and validated for assessing HRQoL in 
men with prostate cancer. Changed HRQoL for men with 
metastatic prostate cancer has previously been measured 
with FACT-P in randomised clinical trials, and the results 
can therefore be compared with existing literature.27–29
We chose to comprehensively assess metabolic changes, 
including glucose metabolism measured with OGTT and 
HbA1c, and body composition measured with DXA scans. 
Previous randomised clinical trials on enzalutamide and 
abiraterone have measured following metabolic adverse 
events: plasma glucose, weight and blood pressure.3–6 We 
did not choose to measure non-fasting plasma glucose, 
because the within-subject plasma glucose varies widely, 
and plasma glucose alone fails to diagnose ~30% of 
cases of previously undiagnosed diabetes.30 31 We chose 
to assess glucose metabolism with OGTT and HbA1c 
because the hyperglycaemic disease process is a risk factor 
for microvascular complications, diabetes and cardiovas-
cular disease and may be present without fulfilling the 
criteria for diabetes.30 We chose to measure BMI and 
body composition with DXA scans because both methods 
can identify obesity and associated metabolic and cardio-
vascular risks,32–34 while DXA scans can identify body fat 
which may be a better predictor of metabolic syndrome 
than BMI alone.35 36 We measure LBM with DXA scans, 
because a loss of lean mass can over time contribute to a 
decrease in muscle strength which are important predic-
tors of balance, the occurrence of falls and mortality.37 38
We chose 3-month follow-up to evaluate the treatments 
side effects and at the same time to avoid a pronounced 
influence of disease progression on HRQoL and fatigue. 
In a cohort study of 21 participants metabolic changes 
appeared already after 7–10 days of treatment with 
low-dose prednisolone (6 mg/day).39 Changes in fatigue 
and HRQoL can be experienced within the first 3 months 
of treatment with new androgen pathway inhibitors.27 The 
median time until biochemical progression was 11.1 and 
11.2 months for men with mCRPC treated with AAP and 
enzalutamide, respectively.3 5 However, 14% (74/546) had 
biochemical progression after only 3 months’ treatment 
with AAP; and 8% (70/854) had biochemical progression 
after 3 months’ treatment with enzalutamide.3 5
The lack of blinding can be perceived as a weakness, 
but we find that it is of minor importance and unlikely to 
affect the objectively measured outcomes. Blood samples 
are analysed in an independent laboratory, DXA scans are 
analysed with the same software and outcomes on fatigue 
and HRQoL are reported by participants.
ConClusIon
The aim of this trial is to assess differences in the 
patient-reported and metabolic side effects of enzalut-
amide and AAP. The results may in the future help 
patients and physicians to choose the best tolerated treat-
ment and thereby reduce treatment induced morbidity 
and improve quality of life.
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